Wolverine Blend (BPC-157 / TB-500) (20 mg Vial) Dosage Protocol
Wolverine Blend combines BPC-157 and TB-500 in a single vial — the two most-studied tissue-repair peptides, working through complementary mechanisms. This page covers the 20 mg vial (10 mg BPC-157 + 10 mg TB-500).
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)
Route: Subcutaneous injection | Frequency: Once daily
| Week | Daily Dose (total blend) | Per-Peptide Dose | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | ~250 mcg each | 7.5 units (0.075 mL) |
| Weeks 3–4 | 666 mcg (0.67 mg) | ~333 mcg each | 10 units (0.10 mL) |
| Weeks 5–8 | 1,000 mcg (1.0 mg) | ~500 mcg each | 15 units (0.15 mL) |
For ≤10-unit (≤0.10 mL) administrations during Weeks 1–4, consider using 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Advanced / Loading Phase (Optional)
Some protocols use a higher TB-500 loading dose during the first 2–4 weeks based on clinical monograph recommendations. This schedule uses higher total blend volumes.
Route: Subcutaneous injection | Frequency: Once daily or split twice weekly for TB-500 loading
| Phase | Daily Dose (total blend) | Per-Peptide Dose | Units (mL) |
|---|---|---|---|
| Loading (Weeks 1–4) | 1,500 mcg (1.5 mg) | ~750 mcg each | 22.5 units (0.225 mL) |
| Maintenance (Weeks 5–8) | 1,000 mcg (1.0 mg) | ~500 mcg each | 15 units (0.15 mL) |
Note: Advanced protocols consume peptide supplies faster. Plan vial quantities accordingly.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on a 4–8 week daily protocol (standard approach at ~1 mg/day maintenance).
| Item | Quantity |
|---|---|
| Peptide Vials (BPC-157 + TB-500 20 mg Blend) | 4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials 6 weeks (42 doses): 3 vials 8 weeks (56 doses): 3–4 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 4 weeks: 28 syringes 6 weeks: 42 syringes 8 weeks: 56 syringes |
| Bacteriostatic Water (10 mL bottles) | 4 weeks (2 vials): 6 mL → 1 × 10 mL bottle 6 weeks (3 vials): 9 mL → 1 × 10 mL bottle 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 4 weeks: 56 swabs → recommend 1 × 100-count box 6 weeks: 84 swabs → recommend 1 × 100-count box 8 weeks: 112 swabs → recommend 2 × 100-count boxes |
How It Works
The Wolverine Blend pairs two tissue-repair peptides with complementary mechanisms in a 1:1 ratio.
BPC-157 (Body Protection Compound): A 15-amino-acid gastric peptide. Studied in animal models for cytoprotective effects, tendon and ligament healing, nitric-oxide signaling, angiogenesis, and collagen organization. Acts primarily at local injury sites.
TB-500 (Thymosin Beta-4 Fragment): A synthetic analog of thymosin beta-4's active region. Studied for actin-sequestering activity, systemic cell migration, and wound repair signaling. Distributes systemically rather than acting only locally — complementing BPC-157's local action.
The combination is widely used in connective-tissue research because the two mechanisms reinforce each other: BPC-157 addresses local vascular and cellular repair while TB-500 modulates systemic repair signaling and cell migration.
Research Findings & Notes
- BPC-157 preclinical studies show accelerated tendon, ligament, and muscle healing in rodent models.
- TB-500 / thymosin beta-4 research includes small human trials for wound healing (topical/IV), not this subcutaneous blend format.
- No controlled human trial has specifically tested this 10 mg + 10 mg blended formulation.
- FDA has flagged BPC-157 and TB-500 among bulk substances that may pose significant safety risks in compounding (limited safety data, immunogenicity concerns).
- TB-500 is on the WADA 2026 Prohibited List as a thymosin beta-4 derivative.
- Side effects: injection-site reactions most common; generally well-tolerated in animal models at research doses.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (powder) | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |